PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Poster Psoriasis
P 34
Long-term safety and efficacy of ustekinumab in patients with psoriasis
inadequately responding to methotrexate: Week 52 TRANSIT results
C. Paul 1
L. Puig 2
T. Luger 3
J. Lambert 4
S. Chimenti 5
G. Girolomoni 6
J.-F. Nicolas 7
K. Kragballe 8
E. Rizova 9
S. Mistry 10
P. Bergmans 11
J. Barker 12
K. Reich 13
1 Larrey Hospital, Paul Sabatier University, Toulouse, France
2 Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona,
Spain
3 University of Munster, Munster, Germany
4 Ghent University Hospital, Ghent, Belgium
5 University of Rome, Rome, Italy
6 University of Verona, Verona, Italy
7 University of Lyon, Lyon, France
8 Arhus University, Arhus, Denmark
9 Janssen-Cilag, Issy Les Moulineaux, France
10 Janssen-Cilag Ltd, High Wycombe, UK
11 Janssen-Cilag BV, Tilburg, Netherlands
12 St John's Institute of Dermatology, King's College, London, UK
13 Georg-August University, Hamburg, Germany
Introduction & Objectives: Little evidence is available to guide physicians when
transitioning patients with psoriasis directly from conventional to biologic therapy. We
compared two methods of transitioning from methotrexate (MTX) to ustekinumab
(UST), following inadequate MTX response. The efficacy of escalating UST dose in
patients without an early response was examined.
Materials & Methods: In this 52-week, randomised, open-label study, 490 patients with
moderate to severe plaque psoriasis and inadequate MTX response, defined as Psoriasis
Area Severity Index (PASI) score greater than or equal to10 after greater than or equal
to 8 weeks of MTX (10-25mg/week), were randomised 1:1 to UST with either a)
immediate cessation of MTX (Arm 1), or b) MTX gradually withdrawn over 4 weeks (Arm
85